Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PeptiDream Inc. (PPTDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
22.25-1.30 (-5.52%)
At close: 9:35AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23.55
Open22.25
BidN/A x N/A
AskN/A x N/A
Day's Range22.25 - 22.25
52 Week Range22.25 - 60.33
Volume100
Avg. Volume257
Market Cap3.198B
Beta (5Y Monthly)0.77
PE Ratio (TTM)61.63
EPS (TTM)0.36
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues

    CAMBRIDGE, Mass. & KAWASAKI CITY, Kanagawa Prefecture, Japan, July 29, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and PeptiDream, Inc. (Tokyo Stock Exchange: 4587), the leading peptide-based drug discovery company with its proprietary Peptide Discovery Platform System (PDPS), announced today a license and collaboration agreement to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues

  • GlobeNewswire

    Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting

    Proof-of-Concept Data Demonstrates Broad Therapeutic Potential of Company’s Multi-targeted Antibody Therapy Enhancer (MATE™) PlatformNEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific molecule developed with Kleo’s multi-targeted antibody therapy enhancer (MATE™) conjugation platform. Kleo’s technology was used to create KPMW135 via chemical conjugation of a CD3 binder directly to the anti-CD20 monoclonal antibody rituximab, a drug approved for the treatment of B-cell lymphomas and lymphocytic leukemias. Data showed that KPMW135 increased anti-tumor activity by at least a factor of 10 by adding T cell mediated cytotoxicity to rituximab’s existing mechanism of action. These data are being presented at the 62nd Annual American Society of Hematology (ASH) Meeting, being held Dec 5-8, 2020 in a virtual format.“Using our proprietary MATE technology, we have built a true ‘biosuperior’ agent by adding an additional mechanism of action - potent and specific activation of anti-tumor T cells to destroy tumors - to an existing approved therapeutic antibody, rituximab, without increasing overall toxicity,” said Doug Manion, MD, CEO. “We believe our technology can rapidly improve product profiles in both approved or investigational antibodies and Fc-containing proteins, and we are actively pursuing strategic collaborations in this space.”In vitro studies showed that KPMW135: * maintained the native binding properties of rituximab, with data demonstrating KPMW135’s ability to bind CD16a/FcgRIIIA and FcRn via the Fc domain, as well as CD20 binding on target tumor cells via the Fab domains * induced functional activation of a number of peripheral blood mononuclear cell (PBMC) effector cell types, including NK cells and T cells * T cell activation was target cell dependent and robust (100-fold higher) In vivo cynomolgus study showed that KPMW135: * activated T cells 2-3 fold with a peak at four hours post-dose, compared to an equivalent dose of rituximab, as shown by increased CD69 and CD44 expression * induced a rapid and sustained reduction of B cells, demonstrating CD20 target specific engagement without overt toxicityIn addition to KPMW135, Kleo’s oncology and infectious diseases portfolio includes KP1237, a clinical-stage, CD38-targeting therapy in development for the treatment of multiple myeloma, as well as a hyperimmune globulin mimic (HGM) therapy in development to treat COVID-19.Details of the electronic presentation are as follows:Title: KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created by a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity by Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab Number: 3009 Presenter: Christian Vidal, PhD Program: Oral and Poster Abstracts Session: 625\. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster III Time and Location: Monday, December 7, 2020: 7:00 a.m. – 3:30 p.m. PST Poster Hall (Virtual Meeting)About Kleo Pharmaceuticals, Inc. Kleo Pharmaceuticals is a targeted immunotherapy company that develops fully synthetic bispecific therapies to redirect, enhance or replace antibodies. The company was founded on the groundbreaking research of its scientific founder Dr. David Spiegel at Yale University. Kleo’s synthetic immunotherapy platform uses two chemistry-based approaches – antibody-redirecting molecule (ARM) and multi-targeted antibody therapy enhancer (MATE) - that help redirect and stimulate key components of the immune system to eradicate cancer cells and virulent pathogens. Compared to biologic therapies, Kleo’s compounds are smaller and more versatile, allowing for better tumor/tissue penetration, non-immunogenic for improved safety and higher dose levels, more efficient to produce and potentially orally bioavailable. They can be optimized against specified biological targets or combined with existing cell- or antibody-based therapies. Kleo investors include Biohaven Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc. (Nikkei:PPTDF). For more information, visit www.kleopharmaceuticals.com.CONTACT INFORMATION LifeSci Advisors (Investors) Irina Koffler 646-970-4681 ikoffler@lifesciadvisors.comSusan Kinkead (Media) 415-509-3610 susan@kinkeadcomm.com

  • GlobeNewswire

    Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting

    NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan®) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020. Details of the electronic presentation are as follows:Title: KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created by a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity by Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab Number: 3009 Presenter: Christian Vidal, PhD Program: Oral and Poster Abstracts Session: 625\. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster III Time and Location: Monday, December 7, 2020: 7:00 a.m. - 3 p.m. PST Poster Hall (Virtual Meeting)Kleo’s MATE platform enables site-directed chemical conjugation with off-the-shelf therapeutic antibodies to rapidly add or improve functionality to existing therapies. By MATE-ing a CD3 binder to rituximab, an anti-CD20 therapeutic monoclonal antibody used to treat B-cell lymphomas and lymphocytic leukemias, Kleo is able to retain rituximab’s existing mechanisms of action while adding potent and specific activation of T cells to destroy the tumor. In addition to oncology applications, the MATE platform is also being used to develop Kleo’s COVID-19 hyperimmune globulin mimic (HGM) therapy.About Kleo Pharmaceuticals, Inc. Kleo Pharmaceuticals is a targeted immunotherapy company that develops fully synthetic bispecific therapies to redirect, enhance or replace antibodies. The company was founded on the groundbreaking research of its scientific founder Dr. David Spiegel at Yale University. Kleo’s synthetic immunotherapy platform uses two chemistry-based approaches – antibody-redirecting molecule (ARM) and multi-targeted antibody therapy enhancer (MATE) - that help redirect and stimulate key components of the immune system to eradicate cancer cells and virulent pathogens. Compared to biologic therapies, Kleo’s compounds are smaller and more versatile, allowing for better tumor/tissue penetration, non-immunogenic for improved safety and higher dose levels, more efficient to produce and potentially orally bioavailable. They can be optimized against specified biological targets or combined with existing cell- or antibody-based therapies. Kleo investors include Biohaven Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc. (Nikkei:PPTDF). For more information, visit www.kleopharmaceuticals.com.CONTACT INFORMATION LifeSci Advisors (Investors) Irina Koffler 646-970-4681 ikoffler@lifesciadvisors.comSusan Kinkead (Media) 415-509-3610 susan@kinkeadcomm.com

Advertisement
Advertisement